Xarelto Lawsuit Update: New Xarelto Mass Tort Group in Philadelphia

Xarelto Mass Tort Group Philadelphia

In this article, Attorney Marc Goldich of Bloodthinnerhelp.com writes about the Philadelphia Xarelto mass tort litigation.
BloodThinnerHelp.com reports today on the formation of the Philadelphia Mass Tort Group. The Philadelphia Court of Common Pleas ordered the establishment of a Xarelto mass tort litigation group on January 22, 2015. This order is a result of 75 individual complaints that were filed in the system against the manufacturers of Xarelto. All of these complaints commonly alleged that the blood thinner causes serious injuries and death due to uncontrollable internal bleeding events.

Xarelto Lawsuits Consolidated in Philadelphia

Philadelphia Xarelto Litigation The 75 Xarelto lawsuits were ordered by an administrative judge to be transferred to the Complex Litigation Center for pretrial administration and discovery. These cases are currently still in this phase of litigation. Continue to check back here for more updates on when the litigation moves forward. The lawyers for the manufacturers of Xarelto, Janssen Pharmaceuticals, a subdivision of Johnson&Johnson, and Bayer AG, argued that these cases should not be consolidated in the city of Philadelphia because the manufacturers are headquartered in New York and New Jersey. The lawyers also argued that the cases should be consolidated federally with the rest of the Xarelto lawsuits that have been consolidated into the MDL in Louisiana. The presiding judge rejected both of the defense’s arguments and agreed with the plaintiffs who argued that both of the defendants had considerable ties to the Philadelphia region and it was an appropriate venue for the litigation. A list of the cases currently filed in the Mass Tort Group can be found here. “Consolidating these cases in Philadelphia is a step in the right direction,” Xarelto attorney Marc Goldich states. Because of the Mass Tort Group, the courts will be able to process all the lawsuits in a much more efficient manner by handling discovery, procedural motions, and other legal matters in bulk. “Handling many of these matters at once will bring faster justice and hopefully settlements for the plaintiffs and their families who have been harmed by this drug.”

The Dangers of Xarelto

Xarelto is a prescription blood thinner that was released onto the U.S. market after it was approved by the FDA in 2011. Xarelto works differently than traditional blood thinners because it blocks the chemical in the blood that is responsible for making blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood’s ability to clot in any capacity. Xarelto is more dangerous than other blood thinners because there is no antidote to its anticoagulant effects, meaning that if a patient suffers from a serious internal bleeding event, there is no way to stop the bleeding, leading to serious injuries and death in patients. Many of the lawsuits also allege that the manufacturers had knowledge of these dangers before they released Xarelto onto the market but released the drug anyway. For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
2016-10-25T16:45:17+00:00

About the Author:

Laurence P. Banville, Esq. is the managing partner of Banville Law. He is a regular contributor on several topics including products liability, nursing home abuse and personal injury.

Got a question for Laurence? Call him directly on: 917-633-4808

Leave A Comment